The therapeutic approach to osteoarthritis

Aging Clinical and Experimental Research

Volumn 15, Issue 5, 2003, Pages 405-412

  Mazières, Bernard ^a   Jamard, Bénédicte ^a   Verrouil, Evelyne ^a   Constantin, Arnaud ^a   Laroche, Michel ^a   Cantagrel, Alain ^a  

^a CHU RANGUEIL   (France)

Author keywords

Disease modifying treatment of osteoarthritis; Education; Osteoarthritis; Rehabilitation; Symptomatic treatment of OA

Indexed keywords

ANTIRHEUMATIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CAPSAICIN; CELECOXIB; CHONDROITIN SULFATE; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DEXTROPROPOXYPHENE; DIACETYLRHEIN; DIHYDROCODEINE; GLUCOSAMINE SULFATE; HYALURONIC ACID; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NALBUPHINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB; SEX HORMONE; STEROID;

ADULT; AGE DISTRIBUTION; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARTILAGE CELL; CLINICAL FEATURE; CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DRUG INDICATION; DRUG TARGETING; FEMALE; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HIP ARTHROPLASTY; HORMONE SUBSTITUTION; HUMAN; JOINT EFFUSION; JOINT INSTABILITY; JOINT STIFFNESS; KNEE ARTHROPLASTY; MALE; OBESITY; OSTEOARTHRITIS; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHYSICAL ACTIVITY; PRIMARY PREVENTION; REHABILITATION MEDICINE; RISK ASSESSMENT; SCHOOL CHILD; SECONDARY PREVENTION; SEX DIFFERENCE; SPORT; TREATMENT PLANNING;

ANIMALIA; VALGUS;

EID: 18544402680     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03327361     Document Type: Article

References (21)

1. Van Saase JL, van Romunde LK, Cats A, Vandenbroucke JP, Valkenburg HA. Epidemiology of osteoarthritis: Zoertermeer survey. Comparison of radiologic osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 1989, 48: 271-80.
2. Kuettner KE, Goldberg VM. Osteoarthritic disorders, Vol. 1. Rosemont (IL): American Academy of Orthopaedic Surgeons, 1995 (Introduction).
3. Levy E, Ferme A, Perocheau D, Bono I. Les coûts socioéconomiques de l'arthrose en France. Rev Rhum (Ed. Fr.) 1993; 60: 63S-7S.
4. Gabriel SE. Update on the epidemiology of the rheumatic diseases. Curr Opin Rheumatol 1996; 8: 96-100.
5. Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. Ann Intern Med 1992; 116: 535-9.
6. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998; 41: 1343-55.
7. Hannan MT, Naimark A, Berkeley J, Gordon G, Wilson PWF, Anderson J. Occupational physical demands, knee bending and knee osteoarthritis: results from the Framingham study. J Rheumatol 1991; 18: 1587-92.
8. McAlindon TE, Wilson PW, Alibadi P, Weissman B, Felson DT. Level of physical activity and the risk of radiographic and symptomatic knee osteoarthritis in the elderly: the Framingham study. Am J Med 1999; 106: 151-7.
9. Hannan MT, Felson DT, Anderson JJ, Naimark A, Kannel WB. Estrogen use and radiographic osteoarthritis of the knee in women: the Framingham osteoarthritis study. Arthritis Rheum 1990; 33: 525-32.
10. Zhang Y, McAlindon TE, Hannan MT, et al. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham study. Arthritis Rheum 1998; 41: 1867-73.
11. McAlindon TE, Felson DT, Zhang Y, Hannan MT, Alibadi P, Weissman B. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham study. Ann Intern Med 1996; 125: 353-9.
12. McAlindon TE, Jacques P, Zhang Y, et al. Do antioxydant micronutrients protect against the development and progression of knee osteoarthritis? Arthritis Rheum 1996; 39: 648-56.
13. Burton-Wurster N, Todhunter RJ, Lust G. Animal models of osteoarthritis. In Woessner JF Jr, Howell DS, Eds. Joint cartilage degeneration. Basic and clinical aspects. New-York: Marcel Dekker, 1993: 347-84.
14. Dougados M, Nguyen M, Berdah L, Mazièes B, Vignon E, Lequesne M. Evaluation of the structure-modifying effect of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in osteoarthritis of the hip. Arthritis Rheum 2001; 44: 2539-47.
15. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251-6.
16. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000; 59: 936-44.
17. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43: 1905-15.
18. Brandt KD. Osteoarthritis. In Fauci AS, Braunwald E, Isselbacher KJ, et al, Eds. Harrison's principles of internal medicine, 14th ed, Vol. 1. New York: McGraw-Hill, 1998: 1935-41.
19. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000; 284: 1247-55.
20. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis? N Engl J Med 2000; 343: 1520-8.
21. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum 2003; 48: 12-20.